BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

NCT06793449 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: anti-BCMA CAR-T
BIOLOGICAL: ASCT

Sponsor

Institute of Hematology & Blood Diseases Hospital, China